<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR27">
 <label>27.</label>
 <mixed-citation publication-type="other">Updated data from phase 3 trial of Ibrance (palbocicilib) plus letrozole in ER+, HER2âˆ’ metastatic breast cancer confirm improvement in progression-free survival. 
  <ext-link ext-link-type="uri" xlink:href="https://www.pfizer.com/news/press-release/press-release-detail/updated_data_from_phase_3_trial_of_ibrance_palbociclib_plus_letrozole_in_er_her2_metastatic_breast_cancer_confirm_improvement_in_progression_free_survival" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.pfizer.com/news/press-release/press-release-detail/updated_data_from_phase_3_trial_of_ibrance_palbociclib_plus_letrozole_in_er_her2_metastatic_breast_cancer_confirm_improvement_in_progression_free_survival</ext-link>. Accessed 8 Mar 2020.
 </mixed-citation>
</ref>
